CRVO CRVO
Company Profile ↓Company Overview
CRVO (CRVO) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 151.0% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $4.01M (-58.9% YoY); net profit $-26.97M.
- Trailing 12 Months Year-on-year growth — revenue -58.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 151.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 151.03% |
| 1 Year: | -58.86% |
Stock Price Performance
| 1 Year: | -69.88% |
| 6 Months: | -41.82% |
| 3 Months: | -24.66% |
| 1 Month: | -17.84% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.53 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 151.0% over 5 years.
CONS
- Trading 73.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 1.41M | 1.72M | 1.53M | 2.35M | 3.29M | 1.94M | 1.92M | 1.76M | 322.57K | 0 |
| Gross Profit | 0 | - | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -2.09M | -8.10M | -1.66M | -1.37M | -1.80M | -3.51M | -1.19M | -1.30M | -1.35M | -6.22M | -3.80M | -5.80M | -2.57M | -2.98M | -3.35M | -3.35M | -3.08M | -6.97M | -2.92M | -2.62M | -3.05M | 2.96M | -3.66M | -5.27M | -4.68M | -3.83M | -12.69M | -4.55M | -4.25M | -904.05K | -1.43M | -1.23M | -2.68M | -2.59M | -3.00M | -5.40M | -5.30M | -6.62M | -8.04M | -8.11M |
| Net Income | - | 2.35M | -1.53M | - | - | - | -1.24M | -1.33M | -1.42M | -6.22M | -3.81M | -5.44M | -28.64M | 20.39M | 5.10M | -3.31M | -2.77M | -6.72M | -2.75M | -2.50M | -2.80M | -2.56M | -3.13M | -4.44M | -4.64M | -3.78M | -12.20M | -4.53M | -4.19M | -882.62K | -534.34K | -1.43M | 2.15M | -2.51M | -2.32M | -4.75M | -4.89M | -6.26M | -7.73M | -7.96M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.37 | -0.53 | - | -1.00 | 0.20 | 2,814,316.00 | 3,369,770.00 | 3,371,468.00 | 3,376,230.00 | 3,940,684.00 | 4,693,290.00 | 34,507,496.00 | 51,978,286.00 | 64,011,342.00 | 83,420,184.00 | 101,903,979.00 | 101,903,979.00 | - | - | -1.70 | - | - | -0.70 | - | - | -0.55 | - | - | - | - |
| R&D Expense | - | - | - | 169.33K | 266.91K | 1.27M | 731.91K | 948.76K | 922.23K | 2.35M | 1.44M | 1.94M | 1.01M | 1.18M | 1.76M | 1.83M | 1.39M | 1.17M | 1.70M | 1.52M | 1.74M | 1.53M | 2.17M | 3.14M | 2.92M | 1.97M | 2.11M | 2.43M | 2.11M | 330.54K | 1.83M | 1.96M | 1.79M | 2.81M | 3.77M | 5.13M | 4.84M | 5.11M | 6.04M | 5.14M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.19K | 570.48K | - | - | - | - | - | - | - | - | - | 0 | 7.14M | 9.74M | 4.01M |
| Gross Profit | -170.20K | -1.74M | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -7.64M | -16.43M | -12.80M | -14.61M | -6.41M | -18.37M | -11.35M | -18.96M | -11.55M | -15.97M | -24.68M | -3.48M | -7.81M | -18.23M | -28.29M |
| Net Income | -8.41M | -15.84M | -2.46M | -14.35M | -6.72M | -18.04M | -1.36M | -18.37M | -11.80M | -14.19M | -24.10M | -5.80M | -2.17M | -16.29M | -26.97M |
| Diluted EPS | - | - | - | - | - | -1.76 | -29.11 | 3,242,301.00 | 6,706,509.00 | 53,831,973.00 | 1,946,859.00 | 2,038,891.00 | - | - | - |
| R&D Expense | - | - | 342.92K | 2.86M | 3.88M | 7.25M | 5.09M | 5.75M | 6.62M | 9.43M | 8.50M | 1.34M | 8.44M | 18.80M | 21.82M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 5.58M | 3.67M | - | 18.34M | 42.78M | 2.28M | 17.48M | 26.15M | 18.20M | 24.11M | 27.73M | 37.84M | 4.16M | 9.97M | 43.08M | 22.88M |
| Total Equity | - | - | -18.39M | 6.46M | 38.17M | -41.62K | 9.18M | 21.23M | 15.61M | 20.13M | 24.81M | 34.91M | -33.29M | 7.38M | 39.20M | 18.22M |
| Cash & Equivalents | - | 98.45K | 312.09K | 254.96K | 2.34M | 2.00M | 1.55M | 8.90M | 7.99M | 14.18M | 18.52M | 37.31M | 4.09M | 7.79M | 9.00M | 8.24M |
| Total Liabilities | 5.56M | 3.79M | - | 11.88M | 4.61M | 2.32M | 8.30M | 4.92M | 2.59M | 3.98M | 2.92M | 2.93M | 13.16M | 2.60M | 3.88M | 4.66M |
| Current Liabilities | 4.93M | 3.79M | - | 8.88M | 2.34M | 1.47M | 4.44M | 2.69M | 804.04K | 1.72M | 2.44M | 2.93M | - | - | 3.88M | 4.66M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.98M | -12.02M | -1.18M | -9.03M | -5.19M | -10.77M | -12.33M | -10.77M | -9.86M | -13.55M | -14.50M | -2.57M | -7.45M | -16.53M | -23.45M |
| Investing Cash Flow | -1.38M | -985.89K | - | -50.91K | 2.46M | 8.50M | -447.82K | - | - | 0 | 4.00K | -12.24M | 0 | -28.66M | 18.10M |
| Financing Cash Flow | 3.37M | 13.11M | 1.13M | 30.71M | 2.39M | 1.83M | 20.12M | 9.87M | 16.04M | 17.89M | 33.30M | 0 | 11.15M | 46.40M | 4.59M |
| Capital Expenditure | - | - | - | -50.91K | -40.29K | -2.33K | -447.82K | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | -9.08M | -5.23M | -10.77M | -12.78M | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -423.5% | -304.7% | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -19,002.6% | -2,879.9% | - | - | - | - | - | - | - | - | - | - | -109.3% | -187.2% | -706.2% |
| Net Margin % | -20,925.1% | -2,776.1% | - | - | - | - | - | - | - | - | - | - | -30.4% | -167.3% | -673.1% |
| ROE % | - | - | -38.1% | -37.6% | 16,143.1% | -196.4% | -6.4% | -117.7% | -58.6% | -57.2% | -69.0% | 17.4% | -29.4% | -41.6% | -148.0% |
| ROCE % | -1,183.6% | 14,582.5% | -135.2% | -36.1% | -795.5% | -140.8% | -48.4% | -109.0% | -51.6% | -63.2% | -70.7% | - | - | -46.5% | -155.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CRVO
CervoMed to Share Drug Program Progress at Aug. 11 Chat - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOVGJ3SFQ2ay1SdGhUTTFRZWNPQlk3LWdadmV1eTlMYW9mQjRaYzVXZElPaENha3hPd1BFZFRpTW90dmNRMWxGZkFxN1ItVl9ybEd0WjZhUk9GdXR4VEp2TU40MFBKSlo2UmZvdUE1OTU5YV9uN3lQZllXeEs0VHJBUWk3NDIxN3EzdnQ2SV…
$CRVO stock is down 9% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQSzBBYWFDeElGMmV4V2Nxdl9ablY5bVh4TFF4SDlwNk1WalUxMl81X1ZkTWY4MzljMmdpX3NIcUFYazFUMnRnQ1FHQ3ZLY0F5YlVfeDRVd0VmaHM1Skd5Q2VoVnN0aE8zRXJXSDBHN3RhOVFJSXN1dUtfSHkzeHlydkFndG5OWHBkR3V6RU…
Nasdaq, S&P 500, Dow Futures Rebound Ahead Of PPI Data Even As Iran Tensions Simmer: Why ORCL, CRWV, ADBE, BATL, MU, ADTX Are In Focus - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi_wFBVV95cUxPc3ptOEUtdDdJbGhHLVkwREtJX05JNUxLcGVFb24tZl9ZcEhwTTJNT3VTcTBqalJ6SFJkcEVwU0tXQ1VfZWI4T3VQc3dBWVVIczFrRW4zRERkTXpmZnllNlh4ZHRJZGNmVlZ4SjB1cGZ1X19SYnoxdVJXa2NsMlNhMXlaS05KSEV5akI3Qm…
CervoMed Insiders Lose Out As Stock Sinks To US$2.45 - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNMUp2ck1HQ1hhSmw3TDN6NkRsZGJUakN4QUZSckY5WUJNQ2o4a2FkUWdUSlpKZmJkUFpWNlNtLWw4cXM0cVBtWDkxV2ZvNG1iZW1Ya2VtaTd0dWVPa3JKUG4xck9YVWtOUUJiMWR5b09iSHEyQkNvYTlRbnhqY2kzWHZGZDB3X2Q2ZVlGVm…
CervoMed Inc. Revenue Breakdown – NASDAQ:CRVO - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE11YlN0cjF1MzZaei1OSlc0R3l3MG54cDRYdjJOSk1ZY2k2TEhsS1A4Sl9BTFRDcnBUTlJ4UDlwblZwQUtSbkJMVTNXRlZ6QkNtVEl2cVNrQmNTODYyTmdzMktpbnlIUnRDS1ZRXzFlUWtGNi1hR2w0?oc=5" target="_blank">CervoMe…
These stocks are gapping in today's session - ChartMill
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPTERIajRNLXp2RU56SFVFWndiMVZNQ0pCamxwcmNNbHVrNjRITjY3Y1RuWHZkTk1EMGg1Vmg0R1lPbS1wUGZmMGJPU3FMcFJqeEJ2U0hOWjRjUTdIUXg0MmVmQ2tVck84SHdOXzMwMG5pdDhpTF80ZUd0RnpUNEZQemQ5dDFLZ3RXc1ZoYW…
CRVO — Frequently Asked Questions
What is the current share price of CRVO?
As of 2026-08-05 17:25 PDT, CRVO trades at $2.81 on NASDAQ/NYSE. Its 52-week range is $2.25 to $10.69.
What is the return on equity (ROE) of CRVO?
CRVO has a return on equity (ROE) of -147.98%.
Is CRVO a good stock to buy?
This page provides a data-driven analysis of CRVO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.